Note Receivable - Cutia Therapeutics (HKEX:2487) - Alpha Spread
C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 14.06 HKD -0.28%
Market Cap: 4.3B HKD
Have any thoughts about
Cutia Therapeutics?
Write Note

Cutia Therapeutics
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cutia Therapeutics
Note Receivable Peer Comparison

Comparables:
6160
1801
9926
603392
300122

Competitive Note Receivable Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
C
Cutia Therapeutics
HKEX:2487
Note Receivable
ÂĄ41.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Note Receivable
ÂĄ71.7m
CAGR 3-Years
-20%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Note Receivable
ÂĄ50m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Cutia Therapeutics's Note Receivable?
Note Receivable
41.7m CNY

Based on the financial report for Dec 31, 2023, Cutia Therapeutics's Note Receivable amounts to 41.7m CNY.

What is Cutia Therapeutics's Note Receivable growth rate?
Note Receivable CAGR 1Y
14%

Over the last year, the Note Receivable growth was 14%.

Back to Top